お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:慢性閉塞性肺疾患(COPD)治療薬の世界市場 - 産業洞察、動向、見通し、市場機会の分析 2019年~2026年
市場調査レポート
商品コード
865108

慢性閉塞性肺疾患(COPD)治療薬の世界市場 - 産業洞察、動向、見通し、市場機会の分析 2019年~2026年

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2019 - 2026

出版日: | 発行: Coherent Market Insights | ページ情報: 英文 178 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=109.20円
慢性閉塞性肺疾患(COPD)治療薬の世界市場 - 産業洞察、動向、見通し、市場機会の分析 2019年~2026年
出版日: 2019年05月27日
発行: Coherent Market Insights
ページ情報: 英文 178 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 目次
概要

慢性閉塞性肺疾患(COPD)に関する啓発活動や、COPDの有病率の上昇、新製品の上市などが世界の慢性閉塞性肺疾患(COPD)治療薬市場の主な成長要因となっています。

当レポートでは、慢性閉塞性肺疾患(COPD)治療薬の世界市場を調査し、市場の概要、医薬品クラス・投与経路・流通チャネル・地域別の市場規模の推移と予測、市場の成長要因および阻害要因の分析、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 調査目的と前提条件

  • 調査目的
  • 前提条件
  • 略語

第2章 市場範囲

  • レポートの説明
    • 市場の定義と範囲
  • エグゼクティブサマリー
    • 市場スニペット:医薬品クラス別
    • 市場スニペット:投与経路別
    • 市場スニペット:流通チャネル別
    • 市場スニペット:地域別
  • コヒーレント商談マップ(COM)

第3章 市場力学、規制、動向分析

  • 市場力学
    • 成長要因
    • 阻害要因
    • 市場機会
  • 規制シナリオ
  • 主なハイライト
  • 共同研究開発・合併・買収
  • PEST分析
  • パイプライン分析
  • 疫学

第4章 慢性閉塞性肺疾患(COPD)治療薬市場:医薬品タイプ別

  • イントロダクション
  • 気管支拡張薬
  • ホスホジエステラーゼ4型阻害剤
  • ステロイド
  • その他

第5章 慢性閉塞性肺疾患(COPD)治療薬市場:投与経路別

  • イントロダクション
  • 経口投与
  • 吸入

第6章 慢性閉塞性肺疾患(COPD)治療薬市場:流通チャネル別

  • イントロダクション
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第7章 慢性閉塞性肺疾患(COPD)治療薬市場:地域別

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋地域
  • 中南米
  • アフリカ
  • 中東

第8章 競争環境

  • ヒートマップ解析
  • 企業プロファイル
    • AstraZeneca Plc
    • Orion Corporation
    • Mylan N.V.
    • Boehringer Ingelheim
    • Teva Pharmaceutical Industries Ltd.
    • GlaxoSmithKline plc
    • Novartis AG
    • Sunovion Pharmaceuticals, Inc.
    • CHIESI Farmaceutici SpA

第9章 セクション

  • 参考文献
  • 調査方法
  • Coherent Market Insightsについて
目次

Chronic obstructive pulmonary disease (COPD) presents itself with mild, moderate, and severe symptoms. Treatment of chronic obstructive pulmonary disease (COPD) involves stepwise non-pharmacological and pharmacological interventions. Non-pharmacological interventions include risk reduction (smoking cessation) and preventing and treating co-morbidities (cardiovascular disease, anxiety, depression, and others). Pharmacological interventions include prescribing short acting bronchodilators, long acting bronchodilators, and others.

Market Dynamics

Factors such as awareness initiatives by organizations, increasing prevalence of COPD, and product launches is supporting the global chronic obstructive pulmonary disease (COPD) treatment market growth. For instance, in May 2019, Boehringer Ingelheim and Optimum Patient Care announced the creation of a new patient registry, APEX COPD, to better understand COPD and how it can be typically treated in primary care offices. Such initiatives by industry players are expected to boost global chronic obstructive pulmonary disease (COPD) treatment market over the forecast period. Moreover, pipeline for respiratory diseases and mainly COPD has several potential medications, which is expected to drive global chronic obstructive pulmonary disease (COPD) treatment market growth.

Key features of the study:

  • This report provides in-depth analysis of global chronic obstructive pulmonary disease (COPD) treatment market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018-2026), considering 2017 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights into market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global chronic obstructive pulmonary disease (COPD) treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key companies covered as a part of this study include AstraZeneca Plc, Orion Corporation, Mylan N.V., Boehringer Ingelheim, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Novartis AG, Sunovion Pharmaceuticals, Inc., and CHIESI Farmaceutici SpA
  • Insights from this report would allow marketers and management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global chronic obstructive pulmonary disease (COPD) treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the global chronic obstructive pulmonary disease (COPD) treatment market

Detailed Segmentation:

Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Drug Class:

  • Bronchodilators
    • Beta 2-Agonists
    • Anticholinergics
    • Theophyllines
      • Phosphodiesterase Type 4 Inhibitors
      • Steroids
      • Others

Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Route of Administration:

  • Oral
  • Inhalation

Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Region:

North America

By Drug Class:

  • Bronchodilators
    • Beta 2-Agonists
    • Anticholinergics
    • Theophyllines
      • Phosphodiesterase Type 4 Inhibitors
      • Steroids
      • Others

By Route of Administration:

  • Oral
  • Inhalation

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Country:

  • U.S.
  • Canada

Europe

By Drug Class:

  • Bronchodilators
    • Beta 2-Agonists
    • Anticholinergics
    • Theophyllines
      • Phosphodiesterase Type 4 Inhibitors
      • Steroids
      • Others

By Route of Administration:

  • Oral
  • Inhalation

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Country:

  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe

Asia Pacific

By Drug Class:

  • Bronchodilators
    • Beta 2-Agonists
    • Anticholinergics
    • Theophyllines
      • Phosphodiesterase Type 4 Inhibitors
      • Steroids
      • Others

By Route of Administration:

  • Oral
  • Inhalation

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Country:

  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific

Latin America

By Drug Class:

  • Bronchodilators
    • Beta 2-Agonists
    • Anticholinergics
    • Theophyllines
      • Phosphodiesterase Type 4 Inhibitors
      • Steroids
      • Others

By Route of Administration:

  • Oral
  • Inhalation

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Country:

  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America

Middle East

By Drug Class:

  • Bronchodilators
    • Beta 2-Agonists
    • Anticholinergics
    • Theophyllines
      • Phosphodiesterase Type 4 Inhibitors
      • Steroids
      • Others

By Route of Administration:

  • Oral
  • Inhalation

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Country:

  • GCC
  • Israel
  • Rest of Middle East

Africa

By Drug Class:

  • Bronchodilators
    • Beta 2-Agonists
    • Anticholinergics
    • Theophyllines
      • Phosphodiesterase Type 4 Inhibitors
      • Steroids
      • Others

By Route of Administration:

  • Oral
  • Inhalation

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Country/Region:

  • Central Africa
  • South Africa
  • North Africa

Company Profiles

  • AstraZeneca Plc*
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Key Strategies
    • Recent Developments
  • Orion Corporation
  • Mylan N.V.
  • Boehringer Ingelheim
  • Teva Pharmaceutical Industries Ltd.
  • GlaxoSmithKline plc
  • Novartis AG
  • Sunovion Pharmaceuticals, Inc.
  • CHIESI Farmaceutici SpA

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Class
    • Market Snippet, By Route of Administration
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Regulatory Scenario
  • Key Highlights
  • Research and Development Collaboration, Mergers, and Acquisitions
  • PEST Analysis
  • Pipeline Analysis
  • Epidemiology

4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Drug Class, 2016-2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2017 and 2026 (%)
    • Y-o-Y Growth Analysis, 2018-2026
    • Segment Trends
  • Bronchodilators
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
    • Beta 2-Agonists
    • Anticholinergics
    • Theophyllines
  • Phosphodiesterase Type 4 Inhibitors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
  • Steroids
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)

5. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Route of Administration, 2016-2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2017 and 2026 (%)
    • Y-o-Y Growth Analysis, 2018-2026
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
  • Inhalation
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)

6. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Distribution Channel, 2016-2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2017 and 2026 (%)
    • Y-o-Y Growth Analysis, 2018-2026
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)

7. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Regions, 2016-2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2017 and 2026 (%)
    • Y-o-Y Growth Analysis, For Regions, 2018-2026
  • North America
    • Market Size and Forecast, By Drug Class, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Route of Administration, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016-2026 (US$ Mn)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Drug Class, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Route of Administration, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016-2026 (US$ Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug Class, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Route of Administration, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016-2026 (US$ Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of APAC
  • Latin America
    • Market Size and Forecast, By Drug Class, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Route of Administration, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016-2026 (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Africa
    • Market Size and Forecast, By Drug Class, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Route of Administration, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Country/Region, 2016-2026 (US$ Mn)
    • Central Africa
    • South Africa
    • North Africa
  • Middle East
    • Market Size and Forecast, By Drug Class, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Route of Administration, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016-2026 (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East

8. Competitive Landscape

  • Heat Map Analysis
  • Company Profiles
    • AstraZeneca Plc
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Orion Corporation
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Mylan N.V.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Boehringer Ingelheim
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Teva Pharmaceutical Industries Ltd.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • GlaxoSmithKline plc
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Novartis AG
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Sunovion Pharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • CHIESI Farmaceutici SpA
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

9. Section

  • References
  • Research Methodology
  • About us and Sales Contact
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.